Craig B. Granowitz - Feb 28, 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Chief Medical Officer
Signature
/s/ Craig B. Granowitz, M.D., Ph.D.
Stock symbol
LXRX
Transactions as of
Feb 28, 2025
Transactions value $
-$43,756
Form type
4
Date filed
3/3/2025, 04:31 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +27.9K +58.62% 75.5K Feb 28, 2025 Direct F1
transaction LXRX Common Stock Options Exercise +35.8K +47.38% 111K Feb 28, 2025 Direct F1
transaction LXRX Common Stock Options Exercise +74.2K +66.67% 186K Feb 28, 2025 Direct F1
transaction LXRX Common Stock Tax liability -$43.8K -65.3K -35.2% $0.67 120K Feb 28, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -27.9K -100% 0 Feb 28, 2025 Common Stock 27.9K Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -35.8K -50% 35.8K Feb 28, 2025 Common Stock 35.8K Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -74.2K -33.33% 148K Feb 28, 2025 Common Stock 74.2K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.